Status:
NOT_YET_RECRUITING
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
PSMA PET/CT
Prostate Cancer
Eligibility:
MALE
40+ years
Phase:
NA
Brief Summary
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy
Eligibility Criteria
Inclusion
- Age ≥40 years, male;
- Serum PSA level 4-20 ng/mL;
- Serum PSA level 4-20 ng/mL;
- No contraindications to PSMA-PET/CT or MRI;
- Signed informed consent.
Exclusion
- Serum PSA \>20 ng/mL;
- History of prostate surgery/radiotherapy;
- Acute prostatitis;
- Coagulation disorders or active infection;
- Severe internal/external hemorrhoids, perianal, rectal, or gluteal lesions;
- Allergy to local anesthetics;
- Inability to tolerate the biopsy procedure.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06901492
Start Date
June 1 2025
End Date
June 1 2028
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006